<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03703401</url>
  </required_header>
  <id_info>
    <org_study_id>IRAS ID 232650</org_study_id>
    <nct_id>NCT03703401</nct_id>
  </id_info>
  <brief_title>The Role of Hydrosalpinx in Recurrent Miscarriage</brief_title>
  <official_title>The Role of Hydrosalpinx in Recurrent Miscarriage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tommy's Charity</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Miscarriage affects one in five pregnancies and little progress has been made in
      understanding and treating this distressing condition. C. trachomatis is the most common
      sexually transmitted infection in the UK. C. trachomatis infection can have serious health
      consequences, including fallopian tube damage. Untreated C. trachomatis infection and tubal
      damage have been associated with miscarriage and adverse pregnancy outcomes such as preterm
      birth, low birth weight and stillbirth. A cohort study is needed to establish the prevalence
      of tubal disease in women with recurrent miscarriages. HyCoSy will be performed to identify
      tubal disease and establish the magnitude of the problem in the recurrent miscarriage
      population. The prognosis of tubal disease on miscarriage and other obstetric outcomes, and
      the role of medical interventions such as tubal surgery (to treat hydrosalpinx) on reducing
      miscarriage and adverse obstetric outcomes will also be studied.

      Objectives

        1. Establish the prevalence of hydrosalpinx in the recurrent miscarriage population.

        2. Establish the prognosis of women diagnosed with recurrent miscarriage with concurrent
           hydrosalpinx.

        3. Explore the role of tubal surgery for improving reproductive outcomes in women with
           recurrent miscarriage population and hydrosalpinx.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2018</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hydrosalpinx</measure>
    <time_frame>12 months</time_frame>
    <description>The presence or absence of tubal blockage and hydrosalpinx</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Miscarriage</measure>
    <time_frame>12 months</time_frame>
    <description>The loss of a pregnancy below 24 completed week of gestation</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">203</enrollment>
  <condition>Abortion, Spontaneous</condition>
  <condition>Miscarriage, Recurrent</condition>
  <condition>Hydrosalpinx</condition>
  <arm_group>
    <arm_group_label>Women with recurrent miscarriage and no hydrosalpinx</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Women with recurrent miscarriage and concurrent hydrosalpinx</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Women with recurrent miscarriage and treated hydrosalpinx</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Hysterosalpingo-contrast-sonogram</intervention_name>
    <description>A contrast ultrasound scan to examine fallopian tube pathology and blockage</description>
    <arm_group_label>Women with recurrent miscarriage and concurrent hydrosalpinx</arm_group_label>
    <arm_group_label>Women with recurrent miscarriage and no hydrosalpinx</arm_group_label>
    <arm_group_label>Women with recurrent miscarriage and treated hydrosalpinx</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women who have suffered from 2 or more pregnancy losses
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-45

          -  Women diagnosed with recurrent miscarriage i.e. 2 or more miscarriages

          -  Ability to give informed consent

        Exclusion Criteria:

          -  Allergy to contrast media used for Hysterosalpingo-contrast-sonogram

          -  Allergy to sonographic gel used for ultrasound scanning

          -  Anatomical anomaly meaning transvaginal ultrasound scan not possible

          -  Stenosed/occluded cervix meaning contrast media unable to be introduced via cervix

          -  Inability to give informed consent

          -  Pregnant at the time of recruitment

          -  Declined recruitment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Must be genetically female as must have suffered from previous pregnancy losses</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jayasish Ghosh, MBBS</last_name>
    <phone>0121 472 1377</phone>
    <phone_ext>5831</phone_ext>
    <email>jayasish.ghosh@nhs.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Birmingham Womens Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>West Midands</state>
        <zip>B15 2TG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jayasish Ghosh, MBBS</last_name>
      <phone>0121 472 1377</phone>
      <phone_ext>5831</phone_ext>
      <email>jayasish.ghosh@nhs.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 9, 2018</study_first_submitted>
  <study_first_submitted_qc>October 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2018</study_first_posted>
  <last_update_submitted>October 9, 2018</last_update_submitted>
  <last_update_submitted_qc>October 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Birmingham</investigator_affiliation>
    <investigator_full_name>Dr Jayasish Ghosh</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Spontaneous</mesh_term>
    <mesh_term>Abortion, Habitual</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 28, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT03703401/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

